5-(苄基氨基甲酰基)-吲哚类化合物及其在制备防治糖尿病心肌病药物中的应用
By preparing 5-(benzylcarbamoyl)-indole compounds, the limitations of existing treatments for diabetic cardiomyopathy have been overcome, achieving effective reduction of blood glucose and improvement of myocardial damage, while reducing side effects, thus providing a new treatment option for diabetic cardiomyopathy.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- GUANGZHOU MEDICAL UNIV
- Filing Date
- 2025-11-28
- Publication Date
- 2026-07-17
AI Technical Summary
Existing treatments have limited effectiveness in addressing myocardial fibrosis and mitochondrial dysfunction in diabetic cardiomyopathy (DCM), and traditional PPARγ agonists have cardiovascular side effects. There is a lack of targeted drugs that combine metabolic regulation and myocardial protection.
Develop 5-(benzylcarbamoyl)-indole compounds and prepare 1-(substituted benzyl)-5-(benzylcarbamoyl)-1H-indole-2-carboxylic acid derivatives by reacting with nitrobenzyl halide or its derivatives, for use in the preparation of drugs for the prevention and/or treatment of diabetic cardiomyopathy.
It effectively lowers blood sugar, improves H9C2 myocardial cell damage induced by high sugar and high fat, significantly improves the efficacy of diabetic cardiomyopathy, has few side effects, shows significant effects at low doses, and has strong binding affinity to PPARγ, moderate activation capacity, and reduces cardiovascular side effects.
Smart Images
Figure CN121591637B_ABST